Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $70.0 million.

  • Vanda Pharmaceuticals' Cash & Equivalents fell 3032.43% to $70.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year decrease of 3032.43%. This contributed to the annual value of $102.3 million for FY2024, which is 2466.85% down from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Cash & Equivalents of $70.0 million as of Q3 2025, which was down 3032.43% from $81.0 million recorded in Q2 2025.
  • Vanda Pharmaceuticals' Cash & Equivalents' 5-year high stood at $354.2 million during Q1 2023, with a 5-year trough of $49.4 million in Q3 2022.
  • Moreover, its 5-year median value for Cash & Equivalents was $100.5 million (2024), whereas its average is $108.3 million.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' Cash & Equivalents skyrocketed by 42919.0% in 2023, and later plummeted by 6466.17% in 2024.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Cash & Equivalents stood at $52.1 million in 2021, then surged by 159.32% to $135.0 million in 2022, then grew by 0.59% to $135.8 million in 2023, then decreased by 24.67% to $102.3 million in 2024, then plummeted by 31.56% to $70.0 million in 2025.
  • Its Cash & Equivalents was $70.0 million in Q3 2025, compared to $81.0 million in Q2 2025 and $111.8 million in Q1 2025.